In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
about
Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and ImagingTargeted therapy using nanotechnology: focus on cancerImproving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysNanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitorsTargeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.Clinical Translation of Nanomedicine.Imaging and drug delivery using theranostic nanoparticlesRecent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingCodelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer TherapyEfficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramTreatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in miceOptimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations.Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.Biological rationale for the design of polymeric anti-cancer nanomedicines.Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.Anthracycline dose intensification in young adults with acute myeloid leukemia.Improving nucleoside analogs via lipid conjugation: Is fatter any better?A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways.DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.Development of cytarabine prodrugs and delivery systems for leukemia treatment.Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.Novel and emerging drugs for acute myeloid leukemiaLate-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications.Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.Novel therapeutics in acute myeloid leukemia.Materials innovation for co-delivery of diverse therapeutic cargos.Novel drugs for older patients with acute myeloid leukemia.Nanomedicine: a pharma perspective.Nanomedicine strategies for hematological malignancies: what is next?Programmable nanomedicine: synergistic and sequential drug delivery systems.Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment.Pleiotropic Role of Dietary Phytochemicals in Cancer: Emerging Perspectives for Combinational Therapy.
P2860
Q26778234-5A81CC30-79D7-41B1-85D5-4785894C971EQ27023361-14B5BFEF-2EDD-4796-B391-71E8F6A4BE2DQ28077848-605711DB-7F29-41BB-AD15-97EAF9CE8F0EQ28818166-5D709675-C1BD-4595-BCDC-896273396A9FQ30279055-D360A837-8E2C-46FE-9F13-492B7A40CED2Q30355939-046358A9-BDEA-4A88-9BD6-0E276254541DQ30449480-34F84D0B-9C7A-4730-A843-A35B30F83E1BQ30456053-5DB71F9E-92E2-49B6-BE21-A3783F787C3DQ33598842-54F8B354-8872-48E7-8EBF-FD10A3901E15Q33859472-075BE1CB-D93A-41A0-8B27-D3EEFB4F9C2FQ34543909-5473D82E-D17D-4589-BF4D-385FB6F67AD3Q34693012-73A706C2-7F49-4BE0-984B-9BB2DE63AF4EQ35556561-470B77B4-5CCC-40CE-B9E2-181B82C030F7Q35692141-099CD03C-7BD0-49D4-AA8D-1776C559C889Q35751958-2CD6D2F1-2D15-4DC5-9478-21E692AA0111Q35905061-65293001-D20C-4CF7-926A-EE984E9AD757Q36160333-DA7E1FD1-885A-40F8-832A-D6F6558B7D52Q36219674-6ABE75ED-D29F-4749-92CC-81BFA7D031F8Q36612663-98DC190F-6043-42F8-B1B4-FD3486EBB256Q36706248-DED7C9F5-7ADC-4005-94BD-5CD8FC9FB602Q36767541-496A4851-628D-4DB7-A82E-5C1DBF59EC86Q37621452-D25DA0AB-3C87-4F52-B1D1-7A6E3B9FA1CBQ37709177-808D2651-692B-4AC6-9314-8CDA9CA677B7Q37801934-D02EB435-C3A8-46F1-8300-66994CD22298Q37813687-4D85688D-2949-4340-9D86-228B957839BBQ37938830-EA10BA0F-16DF-484B-9B6A-B22431BF63D5Q38000711-CBAACA2E-C727-4834-A221-F3C7E1C536C2Q38042705-B0E6BCB2-88B4-48E7-A1C2-47D689E35BA6Q38098301-5F2594E5-2278-452B-B5A1-163EEBEF9CF9Q38103753-F6117B8B-7C93-438A-8759-695684349D59Q38155455-601B745C-8D04-4CD4-A9D2-33AC4055D01BQ38183852-46F52EB3-0B3D-451F-B800-E2B26F8D4044Q38196346-28D44576-84C0-45A6-9F1A-309757B5FE04Q38211033-76300CE6-8025-4BE9-845B-268E85D4FBE4Q38241761-6D7F3972-C48B-49D4-83CF-C20406424220Q38246663-028F3790-9C49-4A3A-9E7D-F5D604784B71Q38270098-21268F9D-4F80-4115-B219-45C75F422B86Q38336134-8E3B45B6-3CCF-44FD-A9D7-E1EBFD0521E0Q38403675-C14A8E02-FDF6-4F82-918C-E2066F6F23EBQ38584742-65E5B0F0-25E3-4341-9FF8-BB606E18661B
P2860
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
In vivo maintenance of synergi ...... enhances therapeutic efficacy.
@en
In vivo maintenance of synergi ...... enhances therapeutic efficacy.
@nl
type
label
In vivo maintenance of synergi ...... enhances therapeutic efficacy.
@en
In vivo maintenance of synergi ...... enhances therapeutic efficacy.
@nl
prefLabel
In vivo maintenance of synergi ...... enhances therapeutic efficacy.
@en
In vivo maintenance of synergi ...... enhances therapeutic efficacy.
@nl
P2093
P1433
P1476
In vivo maintenance of synergi ...... enhances therapeutic efficacy
@en
P2093
Lawrence Mayer
Natalia Zisman
Natashia Harasym
Paul Tardi
Pierrot Harvie
Sharon Johnstone
Sherwin Xie
Troy Harasym
P304
P356
10.1016/J.LEUKRES.2008.06.028
P577
2008-08-03T00:00:00Z